Literature DB >> 8257359

Protective immune response to Mycoplasma gallisepticum demonstrated in respiratory-tract washings from M. gallisepticum-infected chickens.

A P Avakian1, D H Ley.   

Abstract

Chickens inoculated with Mycoplasma gallisepticum (MG) produced IgA, IgM, and IgG detectable in washings from the upper respiratory tract (URTW; nasal sinuses and turbinates) and lower respiratory tract (LRTW; trachea, lungs, and air sacs). URTW and LRTW from infected chickens had significant protective effects in a MG-inoculated tracheal-ring-organ-culture system. Protective effects in vitro correlated positively with total MG-specific immunoglobulin titer, but not IgA titer, as determined by enzyme-linked immunosorbent assay. URTW and LRTW from infected chickens inhibited attachment of MG to tracheal-ring-organ cultures in a dose-dependent manner. This suggests that chickens produce a protective immune response to MG that locates in the respiratory tract and that attachment inhibition may be responsible for this protective effect.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8257359

Source DB:  PubMed          Journal:  Avian Dis        ISSN: 0005-2086            Impact factor:   1.577


  7 in total

1.  Correlates of immune protection in chickens vaccinated with Mycoplasma gallisepticum strain GT5 following challenge with pathogenic M. gallisepticum strain R(low).

Authors:  Mohammed A Javed; Salvatore Frasca; Debra Rood; Katharine Cecchini; Martha Gladd; Steven J Geary; Lawrence K Silbart
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Postepizootic Persistence of Asymptomatic Mycoplasma conjunctivae Infection in Iberian Ibex.

Authors:  Xavier Fernández-Aguilar; Oscar Cabezón; José Enrique Granados; Joachim Frey; Emmanuel Serrano; Roser Velarde; Francisco Javier Cano-Manuel; Gregorio Mentaberre; Arián Ráez-Bravo; Paulino Fandos; Jorge Ramón López-Olvera
Journal:  Appl Environ Microbiol       Date:  2017-07-17       Impact factor: 4.792

3.  Immune responses induced by replication-defective adenovirus expressing the C-terminal portion of the Mycoplasma hyopneumoniae P97 adhesin.

Authors:  F R Okamba; E Moreau; K Cheikh Saad Bouh; C A Gagnon; B Massie; M Arella
Journal:  Clin Vaccine Immunol       Date:  2007-04-04

4.  Identification and expression of a Mycoplasma gallisepticum surface antigen recognized by a monoclonal antibody capable of inhibiting both growth and metabolism.

Authors:  S Yoshida; A Fujisawa; Y Tsuzaki; S Saitoh
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

5.  Growth and humoral immune effects of dietary Original XPC in layer pullets challenged with Mycoplasma gallisepticum.

Authors:  K E C Elliott; S L Branton; J D Evans; S A Leigh; E J Kim; H A Olanrewaju; G T Pharr; H O Pavlidis; P D Gerard; E D Peebles
Journal:  Poult Sci       Date:  2020-03-18       Impact factor: 3.352

6.  Levels of pathogen virulence and host resistance both shape the antibody response to an emerging bacterial disease.

Authors:  Daisy E Gates; Molly Staley; Luc Tardy; Mathieu Giraudeau; Geoffrey E Hill; Kevin J McGraw; Camille Bonneaud
Journal:  Sci Rep       Date:  2021-04-15       Impact factor: 4.379

7.  Evaluation in broilers of aerosolized nanoparticles vaccine encapsulating imuno-stimulant and antigens of avian influenza virus/Mycoplasma gallisepticum.

Authors:  Taha Kumosani; Soonham Yaghmoor; Wesam H Abdulaal; Elie Barbour
Journal:  BMC Vet Res       Date:  2020-08-31       Impact factor: 2.741

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.